IMR Press / CEOG / Volume 39 / Issue 4 / pii/1630475827889-1548726116

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Intrauterine balloon tamponade as management of postpartum haemorrhage and prevention of haemorrhage related to low-lying placenta
Show Less
1 Department of Health Sciences, University of L’Aquila, L’Aquila
2 Department of Surgical Sciences, University of L’Aquila, L’Aquila
3 Obstetrics and Gynecology, “Mazzoni” Hospital, Ascoli Piceno (Italy)
Clin. Exp. Obstet. Gynecol. 2012, 39(4), 498–499;
Published: 10 December 2012
Abstract

The aim of the present study was to evaluate the effectiveness of Bakri balloon in preventing and treating postpartum haemorrhage (PPH). Intrauterine Bakri balloon was used in a total of 16 patients with two different purposes: prophylactic placement of the balloon after cesarean section (CS) in six patients with low-lying placenta and therapeutic placement in ten patients with persistent bleeding from uterine atony, after spontaneous delivery, and administration of uterotonics. Intrauterine Bakri balloon was a successful approach in controlling and preventing PPH in all 16 patients. The median nadir hematocrit was 26.6% in six patients who underwent CS and 25.6% in ten patients with persistent bleeding after spontaneous delivery. The intrauterine balloon was in place for a duration of 24 hours. The median balloon infusion volume was 345 ml (range 250-455). No complications were reported. Bakri balloon tamponade was a useful measure in treating PPH unresponsive to pharmacological therapy in patients who delivered vaginally. Moreover, it was able to prevent persistent bleeding in patients who underwent CS for central placenta previa.
Keywords
Postpartum bleeding
Uterine tamponade
Balloon technology
Fertility sparing
Share
Back to top